Document is current
Any future updates will be listed below
-
Authors
Choi, JungMin
Han, Kyung‑Do
Lee, So‑Ryoung
Lee, Kyung-Yeon
Ahn, Hyo-Jeong
Kim, Bongseong
Oh, Seil
Lip, Gregoryn Y. H.
Choi, Eue‑Keun
-
Funding
Funding for this research was provided by:
Ministry of Health & Welfare, Republic of Korea (RS-2021-KH119931)
Korea government (IRIS RS-2024-00340590)
- License Information
-
More Information
Article History
Received: 19 September 2025
Accepted: 28 January 2026
First Online: 10 February 2026
Declarations
:
: SRL: Speaking fees from Bayer, BMS/Pfizer, Biosense Webster, Daiichi-Sankyo, Sanofi-Aventis, Daewoong Pharmaceutical Co., Samjinpharm, Seers Technology, Biotronik, Boston Scientific, and Medtronic. Consultant for Biosense Webster. EKC: Research grants or speaking fees from Abbott, Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daewoong Pharmaceutical Co., Daiichi-Sankyo, DeepQure, Dreamtech Co., Ltd., Jeil. GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Anthos, and Daiichi-Sankyo. GYHL is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 899871. No personal fees were received. The remaining authors have nothing to disclose.
